A total of 441 targets were predicted and we noticed that many targets were contacted with several active constituents such as NR3C1, HSD11B2, PTGS2, CYP23B1, and PTGS1, and we speculated the top 10 targets could be important in the treatment of CRC as shown in Supplementary Table S1. This evidence concerns the gene PTGS1 and colorectal carcinoma.